Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hewlett-Packard Company (HPQ)’s Data Analytics Deal With Cerner Corporation (CERN)

Along with voice-recognition technologies from Nuance Technologies which I discussed in a previous article, Cerner’s Millennium and Health Facts solutions will form the backbone for its EHR software. The software unifies patient records on a single platform to improve the efficiency of practices.

Keep an eye on IBM and Accenture
Although Hewlett-Packard Company (NYSE:HPQ) and Cerner’s partnership should prove fruitful for both companies, two other competitors to keep an eye on are International Business Machines Corp. (NYSE:IBM) and Accenture as they are both major players in the data analytics business.

IBM’s most impressive achievement in health care is Watson, the first artificial intelligence medical assistant. Watson received the training of a second-year medical student and “digested” patient records, histories, and research at the renowned Memorial Sloan-Kettering Cancer Center. Through that training, Watson became a medical assistant that could provide treatment options with varying degrees of confidence to clinicians. In other words, while companies like Cerner are accelerating data analytics to enhance EHR software, IBM is using data analytics to fuel the growth of artificial intelligence.

IBM does not report health care revenue separately from services and software, but its 3.3% decline in revenue shows that it is facing similar headwinds as HP in the global enterprise business.

Accenture Plc (NYSE:ACN), a diversified management consulting, technology, and outsourcing company, also recently expanded its footprint in health care IT by acquiring ASM Research, a provider of IT services to U.S. defense and federal health clients. The acquisition is aimed at strengthening U.S. federal health capabilities for military personnel and veterans.

Although the ASM purchase should boost Accenture’s top line in the long run, the company suffered last quarter from its broad diversification. Accenture’s revenue only edged up 0.7% from the prior-year quarter to $7.2 billion, missing the consensus estimate of $7.47 billion. Certain businesses including health care and financial services grew, but others declined and offset those gains.

A Foolish final thought
Although the world of health care IT is growing, it’s not a 100-meter dash to the finish line. The effort to modernize hospitals through faster data analytics, streamlined EHRs, ICD-10 updates, and better wireless networks will be a long, grueling marathon. Investors should expect sluggish, single-digit sales growth from most of these companies over the next few years. Long-term growth should remain positive as they secure more contracts, however.

As seen with HP and Accenture, exposure to other businesses can be a drag on stabilizing or growing their data analytics businesses. Therefore, investors who want better exposure to the growing health care IT market without the unwanted weight of slow-growth businesses should stick with dedicated health care IT companies like Cerner instead.

The article Analyzing HP’s Data Analytics Deal With Cerner originally appeared on Fool.com and is written by Leo Sun.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Accenture. The Motley Fool owns shares of International Business Machines (NYSE:IBM).

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!